Welcome to our dedicated page for MVS news (Ticker: MVS), a resource for investors and traders seeking the latest updates and insights on MVS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MVS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MVS's position in the market.
Microvast Holdings reported Q2 2022 revenues of $64.4 million, a 93.0% increase from Q2 2021's $33.4 million. For YTD 2022, revenue soared 109.2% to $101.1 million. Gross profit also improved, reaching $4.8 million versus a loss of $6.8 million in Q2 2021, driven by increased sales volume despite rising raw material costs. However, operating expenses rose significantly to $50.4 million due to share-based compensation. Microvast maintains a revenue growth outlook of 35% to 45% for FY 2022, with a backlog of $105.3 million.
